Skip to content
Open access

PD-1 on CD8+T cells are low in Behçet's disease and is not normalised with type-I interferon.

Feb 2026 · Clinical and Experimental Rheumatology · 0 citations · 32 references
Medicine

TL;DR

The decreased PD-1 expression on CD8+T cells, along with the decreased PD-1, TIM-3 and TIGIT responses of CD8+T cells upon IFN-I stimulation, demonstrated an altered immune response in Behçet's disease.

Abstract

Objectives

Programmed cell death-1 (PD-1) protein on CD8+T cells may affect disease development as a regulatory molecule through various mechanisms. On the other hand, type-I interferons (IFN-I) are used in autoimmune and autoinflammatory diseases to induce regulatory mechanisms. This study aims to investigate PD-1 molecules on CD8+T cells in Behçet's disease (BD) and their response to IFN-I.

Methods

BD (n=37) patients were compared with age- and sex-matched healthy (n=24) and diseased controls (n=29). Peripheral mononuclear cells (PBMCs) were stained for PD-1, CD45RA and CCR7 molecules on CD3+CD8+T cells. Cells from patients and controls were further activated in vitro by anti-CD3 and interferon (IFN-α/2α1b) and the induction of PD-1, TIM-3 and TIGIT on CD8+T cells was analysed.

Results

PD-1 on CD8+T cells with potentially regulatory functions were significantly lower in BD patients, regardless of disease activity, than in controls. CD3 stimulation of PBMCs induced PD-1 expression in all groups, whereas the addition of interferon to stimulated CD8+T cells produced differential responses: the increase of PD-1 on CD8+T cells in controls was not observed in BD patients. The responsive increase of similar co-inhibitory molecules, TIM-3 and TIGIT, in controls was not seen in BD patients either.

Conclusions

The decreased PD-1 expression on CD8+T cells, along with the decreased PD-1, TIM-3 and TIGIT responses of CD8+T cells upon IFN-I stimulation, demonstrated an altered immune response in BD.

Read PDF

Similar papers

Sep 2026

Functional evaluation of CAR-T anti-CD123 from immune-mediated inflammatory diseases patients for novel pDCs-targeted immunotherapy.

BACKGROUND CAR-T cell therapy (Chimeric Antigen Receptor T cells) is a promising approach for immune-mediated inflammatory diseases (IMIDs). Plasmacytoid dendritic cells (pDCs), which infiltrate tissues and secrete type I interferons (IFN-I), play a central early role in IMIDs and represent an attractive therapeutic ta...

B. Caël, E. Bôle-Richard, Imane Belakri et al. · 0 citations
Open access Aug 2026

PD-1 regulates CD4+ T cell-mediated CD8+ T cell responses in the brain to balance viral control and neuroinflammation

Programmed cell death protein 1 (PD-1) is expressed by T cells during progressive multifocal leukoencephalopathy (PML), a life-threatening brain disease caused by the human-only JC polyomavirus (JCPyV). PD-1 checkpoint immunotherapy has benefited some PML patients, but reasons for its variable outcomes are unclear. Usi...

Arrienne B. Butic, E. Afanasiev, Samantha A. Spencer et al. · 0 citations
Open access Aug 2026

Abatacept Reduces CD319+ (SLAMF7) Cytotoxic T Cells and Cytokine Production in Systemic Sclerosis.

Abatacept selectively modulates CD319/SLAMF7-expressing cytotoxic T cells and suppresses associated pro-fibrotic and pro-inflammatory cytokines, particularly in the fibroproliferative subtype, where CD319+ T cell reductions correlate with clinical improvement.

Mikel Gurrea-Rubio, Laura A. Cooney, Kohei Maeda et al. · 0 citations
Open access Jan 2026

Phenotypic Alterations of CD8+ and CD8− CD56+ NK Cell Subsets in Moderate and Severe COVID‐19 Disease

The COVID‐19 pandemic has created a global health challenge. Severe cases are associated with immune system dysfunction, which can lead to uncontrolled inflammation. There are no published data on the specific roles of natural killer (NK)‐cell subsets and immune checkpoint (IC) molecules in disease severity. Thirty‐fiv...

M. Meggyes, Dávid U. Nagy, Ildiko Toth et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.